Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
University of Utah |
---|---|
Information provided by: | University of Utah |
ClinicalTrials.gov Identifier: | NCT00585442 |
The cardiovascular effects of vitamin D therapy (in humans) have been documented only in patients with known vitamin D deficiency or hyperparathyroidism (a surrogate marker of inadequate vitamin D activity). It is unknown whether the cardiovascular benefits of vitamin D therapy extend beyond these patients to the general hypertensive population. We propose to directly measure the effect of vitamin D therapy on plasma renin activity (PRA), plasma renin concentration (PRC), renin transcription (in mononuclear leukocytes), and blood pressure in hypertensive (but otherwise healthy) patients in a randomized, controlled, experimental trial. This will be the first study to assess vitamin D receptor (VDR) biological (PRA, PRC, renin mRNA, and polymorphisms) and hypertensive activity in patients without vitamin D deficiency. We hypothesize that vitamin D inhibition of renin transcription will produce significant reductions in PRA, PRC, renin transcription, inflammatory cytokines, SBP, and DBP, with potential variation by VDR genotype. Such a result may prove to be significant in the treatment of hypertension, as even modest blood pressure reductions (5 mmHg) are associated with a 14% reduction in mortality due to stroke, a 9% reduction in mortality due to CHD, and a 7% overall reduction in all-cause mortality.
Condition | Intervention |
---|---|
Hypertension Vitamin D Deficiency |
Drug: calcitriol |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Placebo Control, Parallel Assignment |
Official Title: | Effects of Calcitriol (1α, 25-[OH]2 Vitamin D3) on Renin Expression in Hypertensive Patients Without Vitamin D Deficiency |
Enrollment: | 6 |
Study Start Date: | May 2007 |
Estimated Study Completion Date: | June 2008 |
Estimated Primary Completion Date: | June 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
A: Experimental |
Drug: calcitriol
1.0 mcg daily
|
Ages Eligible for Study: | 55 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | Univerisity of Utah ( University of Utah ) |
Study ID Numbers: | 10151812, IRB# 00022714 |
Study First Received: | December 22, 2007 |
Last Updated: | January 2, 2008 |
ClinicalTrials.gov Identifier: | NCT00585442 |
Health Authority: | United States: Institutional Review Board |
Vitamin D Deficiency Calcium, Dietary Cholecalciferol Vitamin D Malnutrition Avitaminosis |
Ergocalciferols Vascular Diseases Nutrition Disorders Calcitriol Deficiency Diseases Hypertension |
Molecular Mechanisms of Pharmacological Action Growth Substances Physiological Effects of Drugs Calcium Channel Agonists Bone Density Conservation Agents Cardiovascular Agents Pharmacologic Actions |
Membrane Transport Modulators Vitamins Therapeutic Uses Vasoconstrictor Agents Cardiovascular Diseases Micronutrients |